Publications
Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients: A GEICO Study.
Oaknin A, Roda D, Gonzalez-Martin A, Chiva L, Garcia-Donas J, de Juan A, Redondo A, Martinez S, Garcia Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A.
Int J Gynecol Cancer. 2011 Jul 1. [Epub ahead of print]
Current management of uterine sarcomas.
García-Martínez E, Egea Prefasi L, García-Donas J, Escolar-Pérez PP, Pastor F, González-Martín A.
Clin Transl Oncol. 2011 May;13(5):307-14.
From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.
Expert Opin Investig Drugs. 2011 May;20(5):591-4.
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
González Martín A.
Int J Gynecol Cancer. 2011 May;21(10 Suppl 1):S6-8.
Introduction. Trabectedin treatment in GYN cancers.
Poveda A.
Int J Gynecol Cancer. 2011 May;21(10 Suppl 1):S1-2.
Early-stage ovarian cancer management: still a challenge.
González Martín A.
Clin Transl Oncol. 2011 Feb;13(2):67-8. No abstract available.
Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I, Oza AM.
Future Oncol 2011 Apr; 7(4):559-68.
Brivanib alaninate in cancer.
Diaz- Padilla, Siu LL.
Expert Opinion Investig Drugs 2011 Apr; 20(4): 577-586.
DNA repair-based mechanisms of platinum resistance in epithelial ovarian cancer. From bench to bedside.
Diaz-Padilla I, Poveda A.
Clinical Ovarian Cancer 2010; 3:29-35.
Molecular characterization of ovarian cancer by gene-expression profiling.
Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.
Gynecol Oncol. 2010 Jul;118(1):88-92.
Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting
González-Martín A, Toledo G, Chiva L.
Clin Transl Oncol 2010;12(6):418-30.
Angiogenesis and ovarian cancer
Gómez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A.
Clin Transl Oncol 2009;11(9):564-71.
Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed
González Martín A.
Clin Transl Oncol 2009;11(9):559-60
The International Symposium on Advanced Ovarian Cancer
Poveda A, Vermorken JB.
Int J Gynecol Cancer. 2009;19 Suppl 2:S1
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial
Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, Fabregat i Mayol X, Mellado B, Rubio Perez MJ, Alonso Carrion L, Casado Herraez A, Calvo Garcia E, Churruca Galaz C, Arcusa Lanza A, Herrero Ibañez A, Adrover Cebrian E, Poveda Velasco A.
Am J Clin Oncol. 2008 Oct;31(5):481-7
Sparing fertility in young patients with endometrial cancer
Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, Gonzalez-Martín A.
Gynecol Oncol 2008;111(2 Suppl):S101-4.
Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update
Poveda A, Gonzalez-Martin A.
Ann Oncol. 2008;19 Suppl 7:vii70-6.
Surgical treatment of recurrent cervical cancer: state of the art and new achievements
Chiva LM, Lapuente F, González-Cortijo L, González-Martín A, Rojo A, García JF, Carballo N.
Gynecol Oncol 2008;110(3 Suppl 2):S60-6.
The current role of neoadjuvant chemotherapy in the management of cervical carcinoma
González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A, Chiva LM.
Gynecol Oncol 2008;110(3 Suppl 2):S36-40.
Conservative management of patients with early endometrial carcinoma: a systematic review
Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V, Granados Galainena L, González Martín A, González Cortijo L, Carballo González N.
Clin Transl Oncol 2008;10(3):155-62.
Ten years of "Optimal Therapy in Advanced Ovarian Cancer. Update" meeting
Poveda A.
Int J Gynecol Cancer 2008;18 Suppl 1:67-70.
Human papillomavirus and cervical cancer prevention
A. Oaknin, P. Barretina.
Clin Transl Oncol 2008;10(12):804-11.
Actualización en cáncer ginecológico 2007: Cáncer de ovario y de cérvix
A. Poveda, A. Casado, MJ. Rubio, A. Oaknin, A. Santaballa, C. Mendiola, A. González, JM del Campo, J. Cueva, J. Casinello
Mfar, S.L. 2008
¿Cáncer de Cérvix? 100 preguntas más frecuentes
MJ. Rubio, A.Oaknin, A. Poveda
Edimsa, 2008 “25 preguntas más frecuentes en Oncología: Cáncer de Ovario” A. Oaknin. Publicaciones Permanyer 2008
Update in the management of ovarian and cervical cancer
A. Poveda, R. Salazar,J.M. Campo, C.Mendiola,J. Casinello, B. Ojeda, J.A.Arranz, A. Oaknin, J. García Foncillas, M.J. Rubio and A. González M
Clin Transl Oncol 2007;9(7):443-51
Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?
González Martín A.
Clin Transl Oncol 2007;9(7):409-11
Molecular biology of cervical cancer
González Martín A.
Clin Transl Oncol 2007;9(6):347-54
Treatment guidelines in ovarian cancer
Poveda Velasco A, Casado Herráez A, Cervantes Ruipérez A, Gallardo Rincón D, García García E, González Martín A, López García G, Mendiola Fernández C, Ojeda González B; GEICO Group.
Clin Transl Oncol 2007;9(5):308-16
Germ cell tumours of the ovary
Guillem V, Poveda A.
Clin Transl Oncol 2007;9(4):237-43
Randomized phase II trial of Carboplatin versus Paclitaxel and Carboplatin in platinum sensitive recurrent advanced ovarian carcinoma. A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study
Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, Cervantes A
Ann Oncol 2005;16:749-755
Gemcitabine in patients with ovarian cancer
Poveda A.
Cancer Treat Rev. 2005;31 Suppl 4:S29-37.
Ovarian cancer: is the news good enough?
Poveda A.
Int J Gynecol Cancer 2005;15 Suppl 3:298-306
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy
González-Martín A; GEICO Group.
Int J Gynecol Cancer 2005;15 Suppl 3:241-6
Medical treatment of epithelial ovarian cancer
González-Martín AJ.
Expert Rev Anticancer Ther. 2004;4(6):1125-43.
Ovarian cancer treatment: what is new?
A. Poveda.
Int J Gynecol Cancer. 2003;13 Suppl 2:241-50.
Is combination chemotherapy superior to single-agent chemotherapy in second line treatment?
Gonzalez-Martin A; GEICO Group.
Int J Gynecol Cancer. 2003;13 Suppl 2:185-91.
Remarks and conclusions on ovarian cancer treatment
Poveda A.
Int J Gynecol Cancer 2001;11 Suppl 1:77-81
Advanced ovarian cancer: update, remarks and conclusions on optimal therapy
Poveda A.
Int J Gynecol Cancer 2000;10(S1):57-60.
Preface
Poveda A, Vermorken JB.
Int J Gynecol Cancer 2000;10(S1):1
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer. A phase II trial of the Spanish Group for Ovarian Cancer
A.Cervantes, C.Mendiola, JM del Campo, B.Massuti, A.Casado, A.Escobedo, A.Moyano, B.Ojeda, A.Poveda and D.Benito.
Semin Oncol 1997;24 (5 Suppl 15):S15-40-S15-43.
Communications to congresses
Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients
B. Ojeda, A. Casado, A. Tibau, A. Redondo, M. Beltran, E. Garcia-Martinez, A. Santaballa, B. Pardo, P. Lianes, I. Bover, J. Garcia-Donas, C. M. Churruca, J. F. Cueva, A. B. Sanchez-Heras, M. M. Gordon-Santiago, A. Arcusa Lanza, A. Lopez-Rodriguez, C. Caballero, M. E. Ortega-Izquierdo, A. González-Martín.
ASCO Congress 2011, abstract e15590
Expression of DNA repair genes as biomarkers of outcome in Epithelial Ovarian Cancer: a GEICO study
A. Poveda, A. Casado, A. Cervantes, M. Tarón, I. Romero, I. Bover, A. González Martín, A. Oaknin, B. Ojeda, J.A. Lopez Guerrero.
ESMO Congress 2010, abstract 979PD
Feasibility of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study
A. Oaknin; D. Roda; A. Gonzalez-Martin; J. Garcia-Donas; A. De Juan; A. Redondo; S. Catot; J.M. Del Campo; X. Perez; A. Poveda.
ESMO Congreso 2009
Phase II study of weekly topotecan in recurrent of metastatic cervical cancer: a GEICO Study
M.J. Rubio, A. Santaballa, Y. García, A. González, I. Bover, E. Calvo, J.A. Contreras, J.M. Del Campo, A. de Juan, A. Poveda.
J Clin Oncol; 26. ASCO congress 2008 (abst. 5591)
Feasibility and Toxicity of modified outpatients regimen of intraperitoneal chemotherapy (IP) in optimally debulked stage III ovarian cancer patients
A. Oaknin, A. Cervantes, J. García, Y. García. A. de Juan, S. Catot, X. Pérez, J.M. Campo, A. González, A. Poveda.
12th Biennal Meeting International Gynecologic Society-IGCS. 2008:406
Early CA-125 response pattern in patients with recurrent ovarian cancer treated with pegilated liposomal doxorrubicin (PLD)
A. Oaknin, P. Barretina, L. Jiménez, X. Pérez, M. Velasco, M. Alsina, B. Pardo, J. Brunet, J.R. Germá, M. Beltran.
Ann Oncol; 19 (suppl 8). ESMO congress 2008: 680P.
Early stages (I-IIA) epithelial ovarian cancer (EOC): Preliminary data of the prospective register of the Spanish Group on Research of Ovarian Cancer (GEICO)
N. Ruíz, JM del Campo, E. Calvo, A. Santaballa, C. Churruca, A. Herrero, A. Casado, N. Lainez, A. Poveda, B. Ojeda.
ESMO congress 2008
“Topotecan in platinum resistant advanced ovarian cancer patients”. Evaluation of activity and prognostic factors of response: preliminary results
A study of Spanish Group for Research on Ovarian Cancer (GEICO). V.Soriano, C.Balañá, M.A.Izquierdo, A.Herrero, J.M. del Campo, A.Cervantes, A.Poveda, I.Bover, A.Casado, A.Arcusa, B.Ojeda, T.Massuti, I.Tusquets, I.Álvarez, E.Calvo.
Ann Oncol 2000 (suppl 4):85
A combination of a fixed dose of Carboplatin plus Paclitaxel and Adriamycin in first-line therapy for advanced ovarian cancer and subopimal surgical cytorreduction A phase I trial of the Spanish Group for Ovarian Cancer Research and treatment (GEICO)
A.Cervantes, A.Poveda, A.González, B.Massuti, C.Balañá, A.Insa.
Eur J Cancer 1999; 35(suppl 4): S239
A phase II trial of high dose single agent paclitaxel as first line therapy in advanced ovarian cancer
A. Cervantes, A. Escobedo, JM del Campo, A. Poveda, MD Benito, JR Germá-Lluch.
Ann Oncol 1996; 7 (suppl 5): 76.